Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rande Is. . .FISHING. . [under $1.50] -- Ignore unavailable to you. Want to Upgrade?

To: Richard Nisbet who wrote (1946)	4/27/1999 11:52:00 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 4766

BJCT a nice bottom fish. Security issues also hot, except for our IEIB. When it does get buy interest, it will really fly.

To: Richard Nisbet who wrote (1946)	4/27/1999 12:42:00 PM
From: John F. Poteraske	Respond to of 4766

BJCT-I've owned this stock for a while. The stock fell a lot down to real cheap levels when the company eliminated a relationship with a major firm(merck)-this involved giving merck preferered long term access to the b-2000. Although when reading the press release was interesting to note that bioject has been actively pursuing discussions with a number of other potential corporate partners-so you never know if something is in the pipeline that may work for the company. The two most interesting products involve 1. Glucotrax System-is a blood glucose monitoring device which is to be a minimally invasive sensor that requires changing only once a day. Suppose to be a preferred alternative for diabetes patients. Also the benefit is continuous readings-help to minimize fluctuations of their blood glucose levels-Expected product launch in Early 2001 2. B-2000-Entered into a research collaboration with GeneMedicine(developing pharmaceuticals that use genes to treat or prevent disease)-working to create an innovative system for delivery. Also with the recent acq. of Vitajet-strategy is to penetrate the home-injection market. 1.5cc needle free injector(roche) is currently submittted to the fda for clearance according to info I have read. also the b-4000 self-injector. Well as you can see-this company has some interesting items happening. It might take a little longer then we want, but I like my chances. Also the relationship with Elan which owns a 20% stake in the project and 15% of bioject. Also nice to see that Hambrecht & Quist benefically owns 7.5% Well that All John

To: Richard Nisbet who wrote (1946)	4/27/1999 8:18:00 PM
From: Baton	Read Replies (1) \| Respond to of 4766

Richard: I think I brought BJCT here several weeks ago. It is living up to my expectations (hopes). The really good thing is that it has moved nearly 100% with absolutely no news. Any hint of good news and I think it will jump back up into the $2 range. No debt, good management, limited downside and huge potential. Not only do they have a needle-less injection system, but they also have a blood glucose monitoring patch that does a real-time readout of blood sugar levels (non-invasive). It has an alarm that alerts the user of potential problems. The CFO told me they were in talks with the US military. Something is up and I expect it to happen soon. Baton